423159-53-9

Upstream product

• 110-52-1 1,4-dibromo-butane 
• 192443-17-7 3-(4-bromophenyl)benzo[d]isothiazol-6-ol 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 586-75-4 4-chlorobenzoyl chloride 
• 192443-68-8 3-(4-bromophenyl)-6-methoxy[d]benzisothiazole 
• 161581-95-9 (4-bromo-phenyl)-(2-fluoro-4-methoxy-phenyl)-methanone 
• 663152-21-4 (2-benzylsulfanyl-4-methoxyphenyl)(4-bromophenyl)methanone 

Downstream Products

• 1348823-49-3 BrH*C₂₁H₂₃BrN₂O₂S 
• 423160-35-4 6-(4-bromo-butoxy)-3-(4-bromo-phenyl)-benzo[d]isothiazole 1,1-dioxide 

Relevant academic research and scientific papers

Oxidosqualene cyclase from Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: A model for the development of novel antiparasitic agents

A series of 25 compounds, some of which previously were described as inhibitors of human liver microsomal oxidosqualene cyclase (OSC), were tested as inhibitors of Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana

Oxidosqualene cyclase (OSC) inhibitors for the treatment of dyslipidemia

Novel inhibitors of oxidosqualene cyclase (OSC) for the treatment of dyslipidemia are reported. Starting point for the chemistry program was a set of compounds derived from a fungicide project which, in addition to high affinity for OSC from Candida albicans, also showed high affinity for the human enzyme (hOSC). Here the evaluation process of different scaffolds is outlined for two representative series, the phenyl substituted benzo[d]isothiazoles and the aminocyclohexanes. The most promising compounds derived from the latter series were further profiled in vivo and showed promising properties with respect to modulation of lipid parameters. Schweizerische Chemische Gesellschaft.